Shanghai Medicilon Overview
- Founded
-
2004

- Status
-
Public
- Employees
-
2,440

- Stock Symbol
-
688202

- Investments
-
1
- Share Price
-
$33.46
- (As of Monday Closing)
Shanghai Medicilon General Information
Description
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.
Contact Information
- No. 585 Chuanda Road
- Pudong New Area
- Shanghai, 201299
- China
Shanghai Medicilon Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$33.46 | $34.20 | $26.33 - $60.92 | $2.98B | 87M | 1.13M | $0.67 |
Shanghai Medicilon Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 2,694,509 | 4,679,378 | 1,434,163 | 499,093 |
Revenue | 247,341 | 180,772 | 96,395 | 65,039 |
EBITDA | 64,804 | 58,233 | 23,608 | 13,282 |
Net Income | 57,875 | 43,708 | 18,728 | 9,635 |
Total Assets | 303,713 | 281,384 | 216,555 | 161,262 |
Total Debt | 22,421 | 6,834 | 7,729 | 0 |
Shanghai Medicilon Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Shanghai Medicilon Comparisons
Industry
Financing
Details
Shanghai Medicilon Competitors (23)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
KBI BioPharma | Formerly VC-backed | Durham, NC | 0000 | 0000 | 000000&0 | 0000 |
000000000 | Formerly VC-backed | Piscataway, NJ | 0000 | 00000 | 000000000 | 00000 |
0000000 | Private Equity-Backed | Ann Arbor, MI | 00000 | 0000000 0000 | ||
0000000 0000000000 | Private Equity-Backed | Newton, MA | 00000 | 00000 | 000000000 | 00000 |
00000 000-000000 0 | Venture Capital-Backed | Beijing, China | 0000000000 0 |
Shanghai Medicilon Executive Team (9)
Shanghai Medicilon Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Chunlin Chen Ph.D | Shanghai Medicilon | Board Member & General Manager | 000 0000 |
Dawei Ma | Shanghai Medicilon | Board Member | 000 0000 |
Guolin Wang | Shanghai Medicilon | Board Secretary | 000 0000 |
Jinye Xu | Shanghai Medicilon | Board Member | 000 0000 |
Shanghai Medicilon Signals
Shanghai Medicilon Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000000 0 | 05-Jul-2017 | 0000000000 | 00.000 | Real Estate Services (B2C) |
Shanghai Medicilon ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
31.28 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
0.000
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
Percentile

Commercial Services
Industry
00 of 450
Rank
Percentile

Business Support Services
Subindustry
00 of 171
Rank
Percentile
